Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2045)
All Articles published online
|
Publishing Process of This Article
|
May 26, 2025 (publication date) through Sep 24, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kaplan N, Kabatas S, Civelek E, Savrunlu EC, Akkoc T, Boyalı O, Öztürk E, Can H, Genc A, Karaöz E. Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study. World J Stem Cells 2025; 17(5): 101675 [PMID: 40503363 DOI: 10.4252/wjsc.v17.i5.101675] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v17/i5/101675.htm |
| Number | Citing Articles |
| 1 |
Tomasz Górnicki, Małgorzata Józkowiak, Krzysztof Data, Dominika Domagała, Julia Niebora, Ewa Okowińska, Anna Kłopot, Magdalena Kulus, Artur Bryja, Sławomir Woźniak, Adam Kamiński, Piotr Chmielewski, Aleksandra Górska, Aleksandra Partyńska, Teresa Wysocka, Marek Spaczyński, Hanna Piotrowska-Kempisty, Piotr Dzięgiel, Paul Mozdziak, Bogusław Czerny, Bartosz Kempisty. Wharton’s jelly mesenchymal stem cells (WJ-MSCs), a “Holy Grail” in tissue bioengineering and reconstructive medicine. Biomedicine & Pharmacotherapy 2025; 192: 118570 doi: 10.1016/j.biopha.2025.118570
|